Eva González‐Barca

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles, Johannes Duell, Eva González‐Barca et al. · The Lancet Oncology · 2020 · 519 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Gonzalo Gutiérrez, Teresa M. Cardesa‐Salzmann, Fina Climent et al. · Blood · 2011 · 319 citations · Full text

Medicine, Immunology, Oncology +16

Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients

Carlota Gudiol, Marta Bodro, Antonella F. Simonetti et al. · Clinical Microbiology and Infection · 2012 · 304 citations · Full text

Life Sciences, Microbiology, Oncology +17

The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

Julia Scarisbrick, Pietro Quaglino, H. Miles Prince et al. · British Journal of Dermatology · 2018 · 236 citations · Full text

Medicine, Oncology, Pathology +16

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Alexandra Valera, Armando López‐Guillermo, Teresa M. Cardesa‐Salzmann et al. · Haematologica · 2013 · 227 citations · Full text

Medicine, Genetics, Oncology +14